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It is now gcncrully acknowledged fhat hormone replacement 
therapy in postmenopausal women results in a significant 
reduction in the risk of coronary heart disease ( I). This cflect 
has been ascribed to a variety of factors such as modification 
of lipid or carbohydrate mctlabolism or changes in blood 
coagulation. Of these factors, changes in lipoprotein profile 
are the most likely cause. I’hey include an increase in high 
density lipoproteins (HDLI and a decrease in low density 
lipoproteins (LDL), the latter as a result of increased catab- 
olism. Higher doses of estrogen lead to an increase in 
triglyceride levels in a dose-dependent manner (2). 
The present study. Another mechanism is suggested by 
the studies of Williams et al. (3) reported in this issue of the 
Journal. These workers report that estrogens may exert an 
independent cardioprotective effec, through direct action on 
coronary dynamics. Impaired vasomotor responses of ath- 
erosclerotic artcrics may contribute to coronary vasospasm 
with its consequences, including atherosclerotic changes 
that can occur after coronary vasospasm. The main conclu- 
sion of these investigators is that intravenous administration 
of estrogen in cynomolgous monkeys changes the short-term 
response of atherosclerotic coronary arteries to intracoro- 
nary infusion of acetylcholine. lnstead of causing vasocon- 
striction, acetylcholine dilates coronary arteries. 
Williams et al. (3) examine several mechanisms tha: may 
account for this effect. among them plaque size and lipid and 
lipoprotein profile including effects on oxidation of lipopro- 
teins and smooth muscle (3). They consider these options 
unlikely. They find that the effect of short-term estrogen 
treatment is not associated with plaque size; short-term 
administration of estrogen does not alter HDL cholesterol. 
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and it is unlikely that estrogen can in uence function of 
smooth muscle receptors w 
Mec~ani5~s of estrogen 
aster&. What then are the reasons for the reversal of the 
effect of acetylcholine by estrogens in atherosclerotic coro- 
nary arteries? The main emphasis is on dilating mediators 
produced by endothelial cells, among them prostacyclin and 
endothelium-derived relaxing factor. Prostacyciin cyclooxy- 
genase and prostacyclin synthetase are activate 
diol in rat aortic smooth muscle (4). As the investigators (3) 
state, it remains unclear whether estrogen modulates pros- 
tanoid production and f~~ct~~~ in atheroscle 
That estrogen also affects production of 
derived relaxing factor is demonstrated by 
antagonistic effect of estrogens on the constricting 
~~cetylcholi~e in fc oral arteries of rabbits. How e 
produce this etfect is not known. Theoretically they could 
act on membrane receptors, on the production of nitric oxide 
or of S-nitrocysteiae (5). Diminished cyclooxygenase func- 
tion has been found in athe: asclerotic vessels on stimulation 
with acetylcholine or lysophosphatidylcholine (61, an endo- 
thelium-dependent vasodilator. Is it possible that estrogen 
all’ects receptor mechanisms’? There is evidence that 
tor upgrading occurs in endothelial cell mem 
Lysophosphatidylcholine, a biologic detergent, apparently 
acts through an increase in membrane viscosity by “repack- 
ing of lipid layers and domain separation” (7). But whether 
estrogens restore memorane fluidity or receptor function is 
not known. Estrogens are vasodilators; for example. sys- 
temic infusion of estrogen in castrated nonpregnant sheep 
results in a dose-dependent increase in uterine blood flow. 
Estrogens are also associated with a significant increase in 
cardiac output and a decrease in systemic vascular resis- 
lance at the time of maximal uterine vasodilation. However, 
these effects have been observed in normal arteries (8). 
Paradoxically, the release of nitrosyl compound is in- 
creased in atherosclerotic vessels, showing that the enzy- 
matic process responsible for the production of nitric oxide 
by tkc vascular endothelium is not impaired (5). Whether 
this occurs as a result of defective incorporation of nitric 
oxide into more potent nitrosylated compounds or of accel- 
erated degradation of endothelium-derived relaxing factor is 
not known. 
Wltat possible effecf cat! acute coronary vasodilatiorr by 
tWrocms kaw on tire progrmsion of atherosclerotic. !?eart 
diseawP We agree with Williams et al. (3) that impaired 
vasomotor responses of atherosclerotic coronary arteries 
can contribute to the pathogenesis of coronary vasospasm; 
this leads to transient myocardial ischemia, may promote 
plaque ruplure and cause thrombosis and myocardial infarc- 
tion. There are mechanisms by which estrogen influences 
lipids. Apparently exogenous estrogen suppresses hepatic 
lipase activity and increases high density lipoprotein choles- 
terol (1). Although the effect of oral contraceptives on the 
progression of coronary heart disease in women is still 
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coronary dynamics in ~~~i~~a~es. It w 
fume research to s~~~~e~~el~~ their 
e3ececr of estrogen alone or 
coronary artery dynamics 
with ace~y~c~~~~~e on 
uantitatively followed. 
ion of in vivs and in vim studies WQUL 
~~rta~t hesdts so far obtained. 
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